Iovance Biotherapeutics is trading 4.01% down at $6.47, despite broader U.S. indexes moving higher on August 13, 2026; no clear company-specific announcement or direct catalyst was identified.
- Shares remain well above the $4.34 close on August 5, following record second-quarter revenue of approximately $99.3 million and stronger Amtagvi demand reported August 6.
- The current move appears unconfirmed and may reflect trading-specific pressure rather than broad-market weakness.